Vorolanib

Drug Profile

Vorolanib

Alternative Names: CM-082; X-82

Latest Information Update: 10 Mar 2017

Price : $50

At a glance

  • Originator Tyrogenex
  • Developer AnewPharma; Tyrogenex; Washington University School of Medicine
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Platelet-derived growth factor beta receptor antagonists; Vascular endothelial growth factor receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Age-related macular degeneration
  • Phase I/II Pancreatic cancer
  • Phase I Renal cell carcinoma
  • No development reported Solid tumours

Most Recent Events

  • 10 Mar 2017 Tyrogenex completes enrolment in its phase II trial for Age-related macular degeneration (Treatment-experienced) in USA and United Kingdom
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in China (PO, Tablet)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Solid-tumours in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top